Attovia Therapeutics, Inc. Common Stock

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. Its products include ATTO-1310, an ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31 for chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31 for AD and other immune-mediated skin diseases such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7 for IBD, a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, including ulcerative colitis (UC) and Crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.